Report: R&D funding for TB dropped almost 5% last year
Global funding for the research and development (R&D) of new tuberculosis (TB) drugs, vaccines, and rapid diagnostic tests dropped 4.6% in 2012, to $627.4 million, after rising every year since 2005, according to a report from the New York–based Treatment Action Group (TAG), which focuses on AIDS and TB.